Therapeutic effect of tislelizumab combined with chemotherapy on patients with advanced NSCLC and its influence on serum tumor markers and T lymphocyte subsets
Objective To explore the therapeutic effect of tislelizumab combined with chemotherapy on patients with advanced non small cell lung cancer(NSCLC)and its influence on serum tumor markers and T lymphocyte subsets.Methods 44 patients with advanced NSCLC were divided into a control group and a study group according to random numerical table,with 22 cases in each group.Patients in the control group were treated with chemotherapy,and patients in the study group were treated with tislelizumab on the basis of chemotherapy in the control group.Patients in both groups were compared in terms of short-term objective curative effect,adverse reactions,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin fragment antigen 21-1(CYFRA21-1),neuron specific enolase(NSE)]and T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+),and quality of life.Results The objective remission rate and disease control rate of the study group were 59.09%and 95.45%,and those of the control group were 27.27%and 72.73%.Compared with the control group,the objective remission rate and disease control rate of the study group were obviously higher(P<0.05).After treatment,the study group had CEA of(28.24±2.91)ng/ml,CA125 of(41.56±4.33)U/ml,CYFRA21-1 of(18.39±1.62)μg/L,and NSE of(15.39±1.61)ng/ml,which were lower than(37.67±3.88)ng/ml,(60.62±6.17)U/ml,(25.21±2.60)μg/L,and(20.19±2.62)ng/ml of the control group(P<0.05).After treatment,the study group had CD3+of(45.82±3.95)%,CD4+of(34.62±3.11)%,and CD4+/CD8+of(1.04±0.12),which were higher than(37.17±2.89)%,(28.68±2.48)%,and(0.91±0.10)of the control group;the study group had lower CD8+of(22.38±2.31)%than(27.62±2.82)%of the control group(P<0.05).The incidence of adverse reactions in the study group was 40.91%,which was not different form 50.00%in the control group(P>0.05).After treatment,the quality of life score of the study group was(84.82±8.62)points,which was higher than(73.59±7.84)points of the control group(P<0.05).Conclusion The curative effect of the combination of tislelizumab and chemotherapy in patients with advanced NSCLC is reliable,which can reduce the level of serum tumor markers,regulate the immune function of patients and improve their quality of life.
TislelizumabChemotherapyAdvanced non small cell lung cancerSerum tumor markersT lymphocyte subsets
NETL
NSTL
万方数据
